SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as a report surfaced regarding security flaws in a battlefield communication system, triggering a sharp sell-off despite the company's rebuttal and claims that the issues were resolved. The community is debating the severity and validity of the report, with some viewing it as a buying opportunity while others express concerns about the company's valuation. Discussions also involve the potential impact on government contracts and the trustworthiness of news sources.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid discussions around Novo Nordisk's potential entry into the telehealth space with an obesity pill, which could impact HIMS' market share, while others are pointing out that weightloss is only a small part of the business. The community is debating whether this news presents a buying opportunity or signals a concerning shift in the competitive landscape, especially since some are looking at the COO exit as a negative catalyst. Some traders are noting technical levels and expressing frustration with the stock's volatile price action and seeming sensitivity to news.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors discuss its potential U.S. expansion and speculate on a possible Nasdaq relisting, with community members pointing to strong fundamentals driving the stock. The company's growth in China, coupled with Starbucks' struggles, is fueling optimism, while others remain cautious due to past accounting issues and the stock's OTC status.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as retail investors and traders discuss its impressive recent gains and potential for future growth within the quantum computing sector. Community members are weighing the possibility of a short squeeze against concerns of overvaluation and a potential offering, while some highlight a recent purchase order announcement. The stock's momentum is drawing attention, with debates swirling around its long-term prospects compared to others in the quantum computing space.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending amid high trading volume and anticipation surrounding potential catalysts, including upcoming airshows and FAA certification progress. The community is actively discussing the possibility of a short squeeze, as well as potential partnerships, with some drawing attention to Tesla's presence in a recent promotional video. Discussions also involve comparisons to sector peer Joby Aviation, with some traders anticipating $ACHR closing the market cap gap.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate its AI spending and monetization strategies, highlighted by a recent report on AI chatbots exploring ad revenue. Community chatter reflects concerns about its recent price action, with some viewing it as a buying opportunity while others express bearish sentiment. Broader discussions include Meta's competition in the AI and AR spaces, particularly around its smart glasses.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending due to speculation surrounding potential US government investment, fueled by the CEO's confirmation of White House discussions; the community is debating the significance of these talks and comparing USAR to other rare earth companies like MP Materials and LAC. Some investors are concerned about potential dilution from share unlocks and insider selling, while others remain optimistic about USAR's role in securing a domestic rare earth supply chain amid increasing geopolitical tensions.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amid speculation of a potential buyout, with community members pointing to increased volume and options activity as possible indicators. Chatter suggests that a big tech company could be interested in acquiring the AI firm to bolster its own AI capabilities. Despite recent financial results and leadership changes, the stock is seeing increased interest.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

CLNN is trending as community members discuss the potential for accelerated approval of its ALS treatment following positive commentary from the FDA. Conversations revolve around the company's cash flow, potential offerings, and the possibility of a data leak driving the recent price movement. Some investors express excitement and relief, while others remain cautious due to past experiences and the need for further positive developments.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is trending amid community discussion around a potential short squeeze and recent gains. Some traders cite the company's fundamentals, upcoming data readouts, and potential for a large upside. Others remain cautious, pointing to past trial failures and ongoing discussions about a possible offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's  What You Should Know

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics PR Newswire NORTH CHICAGO, Ill., Jan...

Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket

This biotech stock is a promising buy, but it does come with risks.

Monopar Therapeutics Inc. ($MNPR)Shares of Monopar skyrocketed over 350% by mid-day Thursday after the Wilmette, Illinois-based micro-cap biotech announced an agreement with AstraZeneca plc’s ($AZN) Alexion rare disease subsidiary to exclusively in-license the latter’s ALXN-1840.&nbsp;The drug candidate is a Phase 3 asset and is being investigated for treating Wilson disease, a&nbsp; rare and progressive genetic condition in which the body’s pathway for removing excess copper is compromised.&nbsp;The agreement calls upon Monopar paying an upfront cash payment and giving AstraZeneca an equity stake. The smaller biotech is also required to make regulatory and sales milestones-based future payments and royalties on future net sales.<figure class="image"><a href="https://stocktwits.com/symbol/MNPR"><img style="aspect-ratio:628/148;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/mnpr_sentiment_224afae297.png" alt="mnpr-sentiment.png" width="628" height="148"></a><figcaption>MNPR sentiment and message volume October 24, 2024, as of 2 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>Monopar said it will be responsible for all future development and commercialization activities.&nbsp;Energy Vault Holdings, Inc. ($NRGV)Retail sentiment toward Westlake Village, California-based Energy Vault contrasted the stock move on Thursday. The stock was down over 7% by mid-Thursday despite the lack of any major catalyst.&nbsp;On Monday, Energy Vault, a sustainable, grid-scale energy storage solutions provider, announced an agreement with Australian energy developer Enervest Group for the deployment of a 1,000 MWh battery energy storage in New South Wales, Australia.&nbsp;The stock jumped 25% over the next two sessions before pulling back.<figure class="image"><a href="https://stocktwits.com/symbol/NRGV"><img style="aspect-ratio:638/147;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/nrgv_sentiment_ad5ef0470a.png" alt="nrgv-sentiment.png" width="638" height="147"></a><figcaption>&nbsp;NRGV sentiment and message volume October 24, 2024, as of 2 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment was ‘extremely bullish’ (97/100) compared to the ‘neutral’ sentiment that prevailed on Wednesday.FREYR Battery, Inc. ($FREY)Luxembourg-headquartered FREYR, which manufactures lithium-ion batteries in its Norwegian facilities, has also found traction with retail investors.&nbsp;The green-energy company’s stock may have received a lift from the news that the European Union Innovation Fund has agreed to award 122 million-euro ($132.05 million) to develop its potential joint venture ‘Cathode Active Material’ manufacturing project in Vaasa, Finland.<figure class="image"><a href="https://stocktwits.com/symbol/FREY"><img style="aspect-ratio:637/145;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/frey_sentiment_6c4bdbd8f7.png" alt="frey-sentiment.png" width="637" height="145"></a><figcaption>FREY sentiment and message volume October 24, 2024, as of 2 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>The retail mood is exceedingly exuberant, with the sentiment score on Stocktwits at 97/100.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/quantumscape-stock-jumps-on-earnings-call-updates/cJ21uofR7Z">QuantumScape Stock Bounces Back After Earnings Call Boost, Tesla Tailwinds: Retail Turns Optimistic</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

These 3 stocks have generated the most bullish sentiment among retailers Thursday afternoon.

Monopar Therapeutics, Energy Vault Holdings, FREYR Battery: 3 Stocks Retailers Are Most Bullish Thursday Afternoon

A micro-cap, clinical-stage biotech and two battery manufacturers elicited the most bullish reaction from retail traders.

Equity

A micro-cap, clinical-stage biotech and two battery manufacturers elicited the most bullish reaction from retail traders.


Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

Monopar secures an exclusive license from AstraZeneca's Alexion for ALXN-1840, aiming to advance treatment for Wilson's disease, a rare genetic disorder.
read more...

Shares of Monopar Therapeutics, Inc. (<a class="mention" data-mention="$MNPR" data-symbol-id="MNPR" href="https://stocktwits.com/symbol/MNPR" target="_blank">$MNPR</a>) soared over 500% on Thursday following a major licensing agreement with AstraZeneca (<a class="mention" data-mention="$AZN" data-symbol-id="AZN" href="https://stocktwits.com/symbol/AZN" target="_blank">$AZN</a>) unit Alexion.&nbsp;The stock hit its highest levels since March 2021 and became the top gainer across U.S. exchanges, with retail sentiment surging into ‘extremely bullish’ territory.Monopar secured the rights to ALXN-1840, an oral treatment for Wilson’s disease, a rare genetic disorder that leads to toxic copper build-up in organs.&nbsp;The company will be responsible for all future global development and commercialization activities.In exchange, Monopar will pay an upfront sum in cash and equity, along with future royalties and milestone payments.&nbsp;Under Alexion’s prior development, ALXN-1840 had already met its primary endpoint in a Phase 3 clinical trial.On Stocktwits, retail sentiment for MNPR jumped to ‘extremely bullish’ (97/100), the highest score this year, driven by a surge in message volume as investors reacted to the breakthrough deal.&nbsp;<stembedurl>https://stocktwits.com/Krystian_v/message/589991504</stembedurl><stembedurl>https://stocktwits.com/Mosconi/message/589994892</stembedurl>Monpar stated that its MD, Co-Founder, and CEO, Chandler Robinson, previously conducted laboratory research on tetrathiomolybdate, published his findings in Science, and helped launch the company behind what became ALXN-1840. The focus was on Wilson disease.Wilson’s disease affects around 1 in 30,000 people in the U.S., causing excess copper to accumulate in the liver, brain, and other organs.&nbsp;The disease can lead to liver failure, neurological symptoms, and psychiatric issues, with many cases suffering irreversible damage.MNPR stock has now surged over 1,500% year-to-date.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/lilm-stock-crashes-after-insolvency-warning/cJ21sAxR7k">Air-Taxi Firm Lilium’s Stock Nosedives On Insolvency Warning: Retail Mood Darkens</a>

Monopar secured the rights to ALXN-1840, an oral treatment for Wilson’s disease, a rare genetic disorder that leads to toxic copper build-up in organs.

Monopar Stock Skyrockets After Agreement With AstraZeneca's Unit On Wilson's Disease Drug: Retail On Cloud Nine

The company will be responsible for all future global development and commercialization activities.

Monopar Stock Skyrockets After Agreement With AstraZeneca’s Unit On Wilson's Disease Drug: Retail On Cloud Nine

The company will be responsible for all future global development and commercialization activities.


Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today

Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans.
read more...

Monopar Therapeutics Inc: Positioned for Growth with Strategic Radiopharmaceutical Pivot and Promising Preclinical Data

JonesTrading analyst Justin Walsh reiterated a Buy rating on Monopar Therapeutics Inc (MNPR Research Report) today and set a price target of $2.0...

Monopar Therapeutics Begins Pioneering MNPR-101-Zr Trial

The latest announcement is out from Monopar Therapeutics Inc (MNPR). Monopar Therapeutics Inc. has reached a pivotal milestone by enrolling the fir...

Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Monopar Therapeutics Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$99.39
Prev Close	$97.21
Open	$99.94
Dividend Yield	0.00%
50-Day Moving Average	$47.80
Beta	0.95
Avg. Volume	62,781.95
PE Ratio	-25.28

52-Week High	$101.06
52-Week Low	$4.50
Market Capitalization	$599.78M
EPS (Annual)	-$4.11
Price to Book	11.41
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

MNPR
Monopar Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MNPR News

MNPR Monopar Therapeutics Inc